Latest news with #DamianRoland
BBC News
23-07-2025
- Health
- BBC News
Abandoned Leicester care home turned into NHS facility
An abandoned care home in Leicester has been turned into a recovery and rehabilitation centre to relieve pressure on the city's first 25 beds have opened at the new Preston Lodge following extensive site is expected to be fully up and running by winter, with a total of 58 facility is designed for patients who no longer need to remain in hospital, but would benefit from a stay in the nurse-led unit before being discharged. Patients are expected to stay at the facility at Preston Lodge, in Kingfisher Avenue, for between 21 and 28 days Roberts, a head of nursing at the University Hospitals of Leicester NHS Trust (UHL), said patients can lose muscle condition during a stay in hospital and the aim of extending their stay is "to get them back to their peak fitness".Patients will also have access to dietitians, occupational therapists, and physiotherapists. Prof Damian Roland, an emergency medicine consultant at Leicester Royal Infirmary, said: "We take patients who are sitting in an acute hospital bed and move them to a place where they get that rehabilitation."That gets the patient well more quickly, prevents them perhaps needing further care, but [it] also releases a bed so that we can release patients from the emergency department and other hospital areas."On an average day, there are about 100 patients in hospital beds in Leicester's three main NHS hospitals who are medically fit but there are issues with discharging them, according to Roland said the project is aligned with the government's 10 year plan for the NHS, which aims to move more care into the community. Rowena Harvey, a deputy chief nurse at UHL, added: "It's not going to solve everything but it's a step on that journey and it's about how we work as a system together to achieve the best outcome for our population."Preston Lodge was a city council-run care home and prior to it being used by the NHS, there had been discussions over it potentially becoming flats.
South Wales Guardian
19-07-2025
- Health
- South Wales Guardian
RSV jab in pregnancy can ‘significantly' cut baby's infection risk, study finds
A team of researchers co-led by the University of Edinburgh said giving pregnant women the respiratory syncytial virus (RSV) vaccine led to a 72% reduction in babies being hospitalised with the virus. RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being admitted to intensive care. It is the main infectious cause of hospitalisation for babies in the UK and globally. The study saw researchers examine 537 babies across England and Scotland who were admitted to hospital with severe respiratory disease in the winter of 2024-25. A total of 391 of the babies tested positive for RSV. The team found mothers of babies who did not have RSV were twice as likely to have received the vaccine before giving birth than the mothers of RSV-positive babies (41% as opposed to 19%). They also found receiving the vaccine more than two weeks before giving birth increased the level of protection, with a 72% reduction in hospital admissions in this group compared with 58% for babies whose mothers were vaccinated at any time prior to delivery. The RSV vaccine was introduced across the UK in the late summer of 2024. The scientists said it works by causing the mother to produce antibodies – proteins which help prevent the virus causing severe infection – which are then passed to the fetus, providing protection from severe RSV for the first six months of their child's life. They recommend women get vaccinated as soon as possible from 28 weeks of pregnancy to provide the best protection, as this allows more time for the mother to generate and pass on protective antibodies to the baby, but the jab can be given up to birth. They also said previous research shows only half of expectant mothers in England and Scotland are currently receiving the RSV vaccine, despite its high success at preventing serious illness. Study lead Dr Thomas Williams, from the University of Edinburgh's Institute for Regeneration and Repair, said: 'With the availability of an effective RSV vaccine shown to significantly reduce the risk of hospitalisation in young infants in the UK, there is an excellent opportunity for pregnant women to get vaccinated and protect themselves and their infants from RSV bronchiolitis this coming winter.' Professor Damian Roland, from the Leicester Hospitals and University and a consultant in paediatric emergency medicine, said: 'Our work highlights the value of vaccination and in keeping with the treatment to prevention principle of the NHS 10 Year plan, we would ask all health care systems to consider how they will optimise the rollout of RSV vaccination for mothers.' The research team was led by the universities of Edinburgh and Leicester, and was funded by the Innovative Medicines Initiative, Respiratory Syncytial Virus Consortium in Europe, the Wellcome Trust, and National Institute for Health and Care Research at Imperial College London. The study is published in the journal The Lancet Child and Adolescent Health.
Leader Live
19-07-2025
- Health
- Leader Live
RSV jab in pregnancy can ‘significantly' cut baby's infection risk, study finds
A team of researchers co-led by the University of Edinburgh said giving pregnant women the respiratory syncytial virus (RSV) vaccine led to a 72% reduction in babies being hospitalised with the virus. RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being admitted to intensive care. It is the main infectious cause of hospitalisation for babies in the UK and globally. The study saw researchers examine 537 babies across England and Scotland who were admitted to hospital with severe respiratory disease in the winter of 2024-25. A total of 391 of the babies tested positive for RSV. The team found mothers of babies who did not have RSV were twice as likely to have received the vaccine before giving birth than the mothers of RSV-positive babies (41% as opposed to 19%). They also found receiving the vaccine more than two weeks before giving birth increased the level of protection, with a 72% reduction in hospital admissions in this group compared with 58% for babies whose mothers were vaccinated at any time prior to delivery. The RSV vaccine was introduced across the UK in the late summer of 2024. The scientists said it works by causing the mother to produce antibodies – proteins which help prevent the virus causing severe infection – which are then passed to the fetus, providing protection from severe RSV for the first six months of their child's life. They recommend women get vaccinated as soon as possible from 28 weeks of pregnancy to provide the best protection, as this allows more time for the mother to generate and pass on protective antibodies to the baby, but the jab can be given up to birth. They also said previous research shows only half of expectant mothers in England and Scotland are currently receiving the RSV vaccine, despite its high success at preventing serious illness. Study lead Dr Thomas Williams, from the University of Edinburgh's Institute for Regeneration and Repair, said: 'With the availability of an effective RSV vaccine shown to significantly reduce the risk of hospitalisation in young infants in the UK, there is an excellent opportunity for pregnant women to get vaccinated and protect themselves and their infants from RSV bronchiolitis this coming winter.' Professor Damian Roland, from the Leicester Hospitals and University and a consultant in paediatric emergency medicine, said: 'Our work highlights the value of vaccination and in keeping with the treatment to prevention principle of the NHS 10 Year plan, we would ask all health care systems to consider how they will optimise the rollout of RSV vaccination for mothers.' The research team was led by the universities of Edinburgh and Leicester, and was funded by the Innovative Medicines Initiative, Respiratory Syncytial Virus Consortium in Europe, the Wellcome Trust, and National Institute for Health and Care Research at Imperial College London. The study is published in the journal The Lancet Child and Adolescent Health.
South Wales Argus
19-07-2025
- Health
- South Wales Argus
RSV jab in pregnancy can ‘significantly' cut baby's infection risk, study finds
A team of researchers co-led by the University of Edinburgh said giving pregnant women the respiratory syncytial virus (RSV) vaccine led to a 72% reduction in babies being hospitalised with the virus. RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being admitted to intensive care. It is the main infectious cause of hospitalisation for babies in the UK and globally. The study saw researchers examine 537 babies across England and Scotland who were admitted to hospital with severe respiratory disease in the winter of 2024-25. A total of 391 of the babies tested positive for RSV. The team found mothers of babies who did not have RSV were twice as likely to have received the vaccine before giving birth than the mothers of RSV-positive babies (41% as opposed to 19%). They also found receiving the vaccine more than two weeks before giving birth increased the level of protection, with a 72% reduction in hospital admissions in this group compared with 58% for babies whose mothers were vaccinated at any time prior to delivery. The RSV vaccine was introduced across the UK in the late summer of 2024. The scientists said it works by causing the mother to produce antibodies – proteins which help prevent the virus causing severe infection – which are then passed to the fetus, providing protection from severe RSV for the first six months of their child's life. Pregnant women are encouraged to get vaccinated as soon as possible from 28 weeks (PA) They recommend women get vaccinated as soon as possible from 28 weeks of pregnancy to provide the best protection, as this allows more time for the mother to generate and pass on protective antibodies to the baby, but the jab can be given up to birth. They also said previous research shows only half of expectant mothers in England and Scotland are currently receiving the RSV vaccine, despite its high success at preventing serious illness. Study lead Dr Thomas Williams, from the University of Edinburgh's Institute for Regeneration and Repair, said: 'With the availability of an effective RSV vaccine shown to significantly reduce the risk of hospitalisation in young infants in the UK, there is an excellent opportunity for pregnant women to get vaccinated and protect themselves and their infants from RSV bronchiolitis this coming winter.' Professor Damian Roland, from the Leicester Hospitals and University and a consultant in paediatric emergency medicine, said: 'Our work highlights the value of vaccination and in keeping with the treatment to prevention principle of the NHS 10 Year plan, we would ask all health care systems to consider how they will optimise the rollout of RSV vaccination for mothers.' The research team was led by the universities of Edinburgh and Leicester, and was funded by the Innovative Medicines Initiative, Respiratory Syncytial Virus Consortium in Europe, the Wellcome Trust, and National Institute for Health and Care Research at Imperial College London. The study is published in the journal The Lancet Child and Adolescent Health.
North Wales Chronicle
19-07-2025
- Health
- North Wales Chronicle
RSV jab in pregnancy can ‘significantly' cut baby's infection risk, study finds
A team of researchers co-led by the University of Edinburgh said giving pregnant women the respiratory syncytial virus (RSV) vaccine led to a 72% reduction in babies being hospitalised with the virus. RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being admitted to intensive care. It is the main infectious cause of hospitalisation for babies in the UK and globally. The study saw researchers examine 537 babies across England and Scotland who were admitted to hospital with severe respiratory disease in the winter of 2024-25. A total of 391 of the babies tested positive for RSV. The team found mothers of babies who did not have RSV were twice as likely to have received the vaccine before giving birth than the mothers of RSV-positive babies (41% as opposed to 19%). They also found receiving the vaccine more than two weeks before giving birth increased the level of protection, with a 72% reduction in hospital admissions in this group compared with 58% for babies whose mothers were vaccinated at any time prior to delivery. The RSV vaccine was introduced across the UK in the late summer of 2024. The scientists said it works by causing the mother to produce antibodies – proteins which help prevent the virus causing severe infection – which are then passed to the fetus, providing protection from severe RSV for the first six months of their child's life. They recommend women get vaccinated as soon as possible from 28 weeks of pregnancy to provide the best protection, as this allows more time for the mother to generate and pass on protective antibodies to the baby, but the jab can be given up to birth. They also said previous research shows only half of expectant mothers in England and Scotland are currently receiving the RSV vaccine, despite its high success at preventing serious illness. Study lead Dr Thomas Williams, from the University of Edinburgh's Institute for Regeneration and Repair, said: 'With the availability of an effective RSV vaccine shown to significantly reduce the risk of hospitalisation in young infants in the UK, there is an excellent opportunity for pregnant women to get vaccinated and protect themselves and their infants from RSV bronchiolitis this coming winter.' Professor Damian Roland, from the Leicester Hospitals and University and a consultant in paediatric emergency medicine, said: 'Our work highlights the value of vaccination and in keeping with the treatment to prevention principle of the NHS 10 Year plan, we would ask all health care systems to consider how they will optimise the rollout of RSV vaccination for mothers.' The research team was led by the universities of Edinburgh and Leicester, and was funded by the Innovative Medicines Initiative, Respiratory Syncytial Virus Consortium in Europe, the Wellcome Trust, and National Institute for Health and Care Research at Imperial College London. The study is published in the journal The Lancet Child and Adolescent Health.
